# Delfi Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delfi-diagnostics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.delfidiagnostics.com
- Total disclosed funding: $332M
- Latest round: Series B (Jun 10, 2022)
- Investors on record: 22

## About

Founded in 2019 by co-founders Alessandro Leal, and Victor Velculescu, and based in Maryland, US, Delfi Diagnostics focuses on analyzing fragments of cell-free DNA to detect cancer accurately from a single blood sample. In June 2024, Delfi Diagnostics, Inc. raised an amount from investors Merck Global Health Innovation Fund.


Delfi Diagnostics’ primary product is a blood-based test for cancer detection, which utilizes advanced machine-learning techniques to analyze fragments of cell-free DNA fragments. By employing machine learning algorithms, Delfi identifies patterns in these fragments that are indicative of cancer. The company emphasizes the ability of their test to detect previously unrecognized markers of cancer compared to existing screening methods.
 
The company will use the June 2024 funding to support the business growth and commercialization of its cancer detection solutions.

## Funding rounds

- Series B, Jun 10, 2022, $225M — Menlo Ventures, OrbiMed Advisors, T Rowe Price, OUP (Osage University Partners), Brown Advisory, Foresite Capital, Windham Venture Partners, Eli Lilly & Company, Open Field Capital, Rock Springs Capital, DFJ Growth, Cowen Investment Management, Illumina Ventures, Point72 Asset Management, Samsara BioCapital, Northpond Ventures, AV8 Ventures, Initiate Ventures, PTX Capital, Point Field Partners
- Series A, Jan 12, 2021, $101M — Menlo Ventures, OrbiMed Advisors, T Rowe Price, OUP (Osage University Partners), Foresite Capital, Windham Venture Partners, Rock Springs Capital, Illumina Ventures, Samsara BioCapital, Northpond Ventures, AV8 Ventures, Cowen Healthcare Investments
- Seed, Aug 12, 2019, $5.5M — Menlo Ventures, Allianz Group, Windham Venture Partners, Illumina Ventures, Samsara BioCapital, AV8 Ventures

## Investors

- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Seed, Series A, Series B
- Allianz Group — Seed
- Windham Venture Partners (https://capitalatlas.ai/funds/windham-venture-partners) — Seed, Series A, Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Seed, Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Seed, Series A, Series B
- AV8 Ventures (https://capitalatlas.ai/funds/av8-ventures) — Seed, Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A, Series B
- Rock Springs Capital — Series A, Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B
- Cowen Healthcare Investments — Series A
- Brown Advisory — Series B
- Eli Lilly & Company — Series B
- Open Field Capital (https://capitalatlas.ai/funds/open-field-capital) — Series B
- DFJ Growth (https://capitalatlas.ai/funds/dfj-growth) — Series B
- Cowen Investment Management — Series B
- Point72 Asset Management — Series B
- Initiate Ventures (https://capitalatlas.ai/funds/initiate-ventures) — Series B
- PTX Capital (https://capitalatlas.ai/funds/ptx-capital) — Series B
- Point Field Partners (https://capitalatlas.ai/funds/point-field-partners) — Series B